Search research articles
Contact Us
Filters
Showing results (21-30 of 193) with videos related to
Page
of 20
Sort By:
American Journal of Physiology. Renal Physiology
|
March 11, 2016
Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?
John D Imig
Frontiers in Physiology
|
August 29, 2022
Frontiers in metabolic physiology grand challenges
John D Imig
Cardiovascular Drug Reviews
|
September 12, 2006
Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors
John D Imig
Clinical Science (London, England : 1979)
|
March 29, 2022
SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection
John D Imig
Kidney360
|
December 18, 2025
NF Erythroid 2-Related Factor 2 Peroxisome Proliferator-Activated Receptor-γ Crosstalk: Reprogramming Monocytic Myeloid-Derived Suppressor Cells in Kidney Disease
John D Imig
Frontiers in Pharmacology
|
October 19, 2020
Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
John D Imig, Christophe Morisseau
Physiological Reports
|
October 26, 2013
Afferent Arteriolar Responses to β,γ-methylene ATP and 20-HETE are not Blocked by ENaC Inhibition
Tasuku Nagasawa, John D Imig
Comprehensive Physiology
|
May 31, 2013
Immune and inflammatory role in renal disease
John D Imig, Michael J Ryan
American Journal of Physiology. Renal Physiology
|
September 11, 2015
Reply to "Letter to the editor: 'Concern regarding quantification of urinary nephrin by commercially available ELISA'"
Jennifer C Sullivan, John D Imig
American Journal of Hypertension
|
March 19, 2011
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome
Abdul Hye Khan, John D Imig
Page
of 20
Search research articles
Search
Showing results (21-30 of 193) with videos related to
Sort By:
Page
of 20
American Journal of Physiology. Renal Physiology
|
March 11, 2016
Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?
John D Imig
Frontiers in Physiology
|
August 29, 2022
Frontiers in metabolic physiology grand challenges
John D Imig
Cardiovascular Drug Reviews
|
September 12, 2006
Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors
John D Imig
Clinical Science (London, England : 1979)
|
March 29, 2022
SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection
John D Imig
Kidney360
|
December 18, 2025
NF Erythroid 2-Related Factor 2 Peroxisome Proliferator-Activated Receptor-γ Crosstalk: Reprogramming Monocytic Myeloid-Derived Suppressor Cells in Kidney Disease
John D Imig
Frontiers in Pharmacology
|
October 19, 2020
Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
John D Imig, Christophe Morisseau
Physiological Reports
|
October 26, 2013
Afferent Arteriolar Responses to β,γ-methylene ATP and 20-HETE are not Blocked by ENaC Inhibition
Tasuku Nagasawa, John D Imig
Comprehensive Physiology
|
May 31, 2013
Immune and inflammatory role in renal disease
John D Imig, Michael J Ryan
American Journal of Physiology. Renal Physiology
|
September 11, 2015
Reply to "Letter to the editor: 'Concern regarding quantification of urinary nephrin by commercially available ELISA'"
Jennifer C Sullivan, John D Imig
American Journal of Hypertension
|
March 19, 2011
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome
Abdul Hye Khan, John D Imig
Page
of 20